Just on the declining EPS, the obvious reason for this is MNY's high cost of capital, being all equity funded and the constant share issues required to expand its capital base.
Once they secure the external debt facility, that will lower the cost of capital and generate better returns.
- Forums
- ASX - By Stock
- SVR
- pleasing annual report
pleasing annual report, page-4
Featured News
Add SVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.29 |
Change
-0.015(1.15%) |
Mkt cap ! $263.1M |
Open | High | Low | Value | Volume |
$1.35 | $1.35 | $1.27 | $35.88K | 27.94K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1215 | $1.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 463 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1215 | 1.280 |
2 | 2143 | 1.275 |
2 | 3500 | 1.270 |
1 | 1055 | 1.265 |
2 | 3000 | 1.260 |
Price($) | Vol. | No. |
---|---|---|
1.285 | 463 | 3 |
1.290 | 350 | 1 |
1.295 | 2823 | 5 |
1.300 | 72232 | 3 |
1.305 | 1005 | 1 |
Last trade - 14.24pm 15/11/2024 (20 minute delay) ? |
Featured News
SVR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online